IMUNON Reports Positive Phase 2 MRD Clinical Data for IMNN-001, Demonstrating the Successful Overcoming of Historical IL-12 Safety Barriers in Frontline Ovarian Cancer
Go back to IMUNON Reports Positive Phase 2 MRD Clinical Data for IMNN-001, Demonstrating the Successful Overcoming of Historical IL-12 Safety Barriers in Frontline Ovarian Cancer| (NASDAQ: IMNN) | Delayed: 1.59 -0.08 (4.79%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.67 | 52 Week High | $ | |||
| Open | $1.70 | 52 Week Low | $ | |||
| Day High | $1.70 | P/E | N/A | |||
| Day Low | $1.55 | EPS | $ | |||
| Volume | 179,328 | |||||
